Department of Otolaryngology-Head & Neck Surgery, University of California, San Francisco, San Francisco, California 94115, USA.
Curr Opin Neurol. 2012 Feb;25(1):57-60. doi: 10.1097/WCO.0b013e32834f038c.
This review highlights recent advances in cochlear gene therapy over the past several years. Cochlear gene therapy has undergone tremendous advances over the past decade. Beginning with some groundbreaking work in 2005 documenting hair cell regeneration using virally mediated delivery of the mouse atonal 1 gene, gene therapy is now being explored as a possible treatment for a variety of causes of hearing loss.
Recent advances in cochlear gene therapy include improved methods of gene delivery with a better delineation of viral vectors that are suitable for this purpose, additional improvements in hair cell regeneration, and directed research toward autoimmune hearing loss, ototoxicity, spiral ganglion survival, and genetic forms of hearing loss.
If successful, cochlear gene therapy will dramatically alter our ability to treat a variety of forms of acquired and genetic hearing loss.
本篇综述重点介绍了过去几年中耳蜗基因治疗的最新进展。过去十年中，耳蜗基因治疗取得了巨大进展。从 2005 年开创性地使用病毒介导的小鼠 atonal 1 基因转导实现毛细胞再生开始，基因治疗现在正被探索作为治疗各种原因听力损失的一种可能方法。
耳蜗基因治疗的最新进展包括改进了基因传递方法，更好地确定了适合该目的的病毒载体，毛细胞再生方面的进一步改进，以及针对自身免疫性听力损失、耳毒性、螺旋神经节存活和遗传性听力损失的定向研究。
如果成功，耳蜗基因治疗将极大地改变我们治疗各种获得性和遗传性听力损失的能力。
